We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK (GSK - Free Report) closed at $36.27 in the latest trading session, marking a -0.3% move from the prior day. This change was narrower than the S&P 500's daily loss of 0.45%. Elsewhere, the Dow lost 0.04%, while the tech-heavy Nasdaq added 3.58%.
Coming into today, shares of the drug developer had gained 6.25% in the past month. In that same time, the Medical sector gained 1.08%, while the S&P 500 gained 5.01%.
Investors will be hoping for strength from GSK as it approaches its next earnings release, which is expected to be July 26, 2023. The company is expected to report EPS of $0.83, down 4.6% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $8.41 billion, down 3.41% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $3.66 per share and revenue of $35.88 billion, which would represent changes of +5.78% and -9.66%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for GSK. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.77% higher. GSK is currently sporting a Zacks Rank of #2 (Buy).
Valuation is also important, so investors should note that GSK has a Forward P/E ratio of 9.95 right now. This represents a discount compared to its industry's average Forward P/E of 18.77.
Investors should also note that GSK has a PEG ratio of 1.81 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.86 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 108, putting it in the top 43% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GSK (GSK) Stock Moves -0.3%: What You Should Know
GSK (GSK - Free Report) closed at $36.27 in the latest trading session, marking a -0.3% move from the prior day. This change was narrower than the S&P 500's daily loss of 0.45%. Elsewhere, the Dow lost 0.04%, while the tech-heavy Nasdaq added 3.58%.
Coming into today, shares of the drug developer had gained 6.25% in the past month. In that same time, the Medical sector gained 1.08%, while the S&P 500 gained 5.01%.
Investors will be hoping for strength from GSK as it approaches its next earnings release, which is expected to be July 26, 2023. The company is expected to report EPS of $0.83, down 4.6% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $8.41 billion, down 3.41% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $3.66 per share and revenue of $35.88 billion, which would represent changes of +5.78% and -9.66%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for GSK. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.77% higher. GSK is currently sporting a Zacks Rank of #2 (Buy).
Valuation is also important, so investors should note that GSK has a Forward P/E ratio of 9.95 right now. This represents a discount compared to its industry's average Forward P/E of 18.77.
Investors should also note that GSK has a PEG ratio of 1.81 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.86 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 108, putting it in the top 43% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.